Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial.
Van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al.
Lancet Oncol. 2014;15(9):966-74.
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic
multicentric Castleman disease.
Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Van Rhee F, Voorhees R, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al.
Blood. 2018;132(15): 2115-24.
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Van Rhee F, Rossi JF, Simpson D, et al.
British Journal of Haematology. 2020 Oct. DOI: 10.1111/bjh.17177.
For clinical paper requests, please contact EUSA Medical Information